Juniper Biomedical Receives $3M Funding

Juniper Biomedical, a Worcester, MA-based medical device company, received $3m in funding.

The company completed a $2M Seed financing led by Auroral Holdings, with participation from Atma Capital, Hub Angels, Beacon Angels and other private investors, and received a $1M award through the NIH Common Fund as a winner of the NIH SPARC Neuromod Prize, a competition designed to accelerate the development of targeted neuromodulation therapies.

The company intends to use the funds to further enhance its expansion plans and solidify its position in the ecosystem, developing innovative neuromodulation solutions.

Led by CEO David Constantine, Juniper Biomedical is developing therapies for women and men who suffer from pelvic health conditions like urinary incontinence, bowel incontinence, pelvic pain, sexual dysfunction, and pelvic floor disorders. Its solutions leverage a precise, low-power neuromodulation micro-implant that delivers a type of therapy to pelvic nerves.

The funding will enable Juniper Biomedical to complete numerous development and commercialization milestones for their platform neuromodulation technology. The company’s first application will offer long-term, precision therapy for patients with mixed urinary incontinence (MUI), which affects nearly 1 in 3 women.